News Feature
TA-65, A Telomerase Activator, Improves Cardiovascular Markers in Patients with Metabolic Syndrome

TA-65, A Telomerase Activator, Improves Cardiovascular Markers in Patients with Metabolic Syndrome



Fernandez ML, Thomas MS, Lemos BS, DiMarco DM, Missimer A, Melough M, Chun OK, Murillo AG, Alyousef H, Medina-Vera I


Telomerase Activator 65 (TA-65), a compound extracted from Astragalus membranaceus has been used in Chinese traditional medicine for extending life span. Scarce information exists on the effects of TA-65 on parameters of metabolic syndrome (MetS).


We recruited 40 patients with MetS to determine the effects of TA-65 on dyslipidemias, hypertension, and oxidative stress in this at-risk population. The study was a double-blind, randomized crossover design in which patients were allocated to consume either 16 mg daily of a TA-65 supplement or a placebo for 12 weeks. Following a 3-week washout, participants were allocated to the alternate treatment for an additional 12 weeks. Anthropometric and biological markers were measured at the end of each treatment. Plasma lipids, glucose, C-reactive protein (CRP), liver enzymes, and glycosylated hemoglobin were measured using a Cobas c-111. Inflammatory cytokines were measured by Luminex technology and markers of oxidative stress by use of spectroscopy.


Compared to the placebo period, HDL cholesterol (HDL-C) was higher while body mass index, waist circumference, and the LDL/HDL ratio were lower (p < 0.05) during TA-65 treatment. In addition, plasma tumor necrosis factor-α (TNF-α) was lower during the TA-65 period (p< 0.05). Positive correlations were observed in changes between the placebo and the TA-65 periods in HDL-C and CRP (r = -0.511, p < 0.01), alanine aminotransferase (r = -0.61, p < 0.001) and TNF-α (r = -0.550, p < 0.001) suggesting that the favorable changes observed in HDL were associated with decreases in inflammation.


TA-65 improved key markers of cardiovascular disease risk, which were also associated with reductions in inflammation.

Copyright© Bentham Science Publishers; For any queries, please email at

For more information or to view the whole article click here.

Telomerase Activator Improves Cardiovascular Markers in Metabolic Syndrome Patients
First randomized, double-blind, placebo controlled study to show telomeres getting longer in humans
New Study Observes the Impact of Telomerase Activation on Metabolic and Cardiovascular Health Markers
Functional Assessment of Pharmacological Telomerase Activators in Human T Cells
Toll-Free: 888.360.8886

ends in the next

check your email for offer details